GlobeNewswire

YouVersion Bible App celebrates 10th anniversary

Dela

Most downloaded Bible app helps change Bible engagement worldwide

 

OKLAHOMA CITY, July 09, 2018 (GLOBE NEWSWIRE) -- This July, YouVersion celebrates the 10-year anniversary of the Bible App, which was one of the first 200 free apps available when Apple launched the App Store on July 10, 2008. In the decade since, the Bible App has been downloaded on more than 330 million devices and in every country of the world.

"We never could have predicted the results we've seen as millions of people around the world have read, listened to, shared, and interacted with the Bible and each other in new ways," said Bobby Gruenewald, Life.Church Pastor, Innovation Leader and YouVersion Founder.

After seeing 83,000 installs of the Bible App in the first three days, it went on to reach 10 million installs in 2010, 50 million installs in 2012, and 100 million installs in 2013. In the last decade, people have used the Bible App to: 

  • Read 70 billion chapters of the Bible 
  • Listen to 12 billion audio chapters of the Bible
  • Make 4 billion Highlights, Bookmarks, and Notes 
  • Complete 2.4 billion Bible Plan days 

"Early on, we discovered that proximity helped us engage with the Bible," said Gruenewald. "As soon as I had access to the Bible on the phone that's always in my pocket, my connection to it naturally became more frequent."

As the Bible App grew, users cited the ability to quickly switch between different versions of the Bible as a favorite feature. The app, which initially launched with 15 versions and two languages, has since partnered with publishers and Bible societies to offer more than 1,700 different versions of the Bible, including Bible text in more than 1,200 languages. 

With smartphones propelling social media platforms to new heights, the YouVersion community quickly adopted social sharing features as they were added to the app. Over the last decade, Bible App users have shared more than 950 million Bible verses, earning the Bible a prominent place in people's lives and social media feeds.

Recognizing the opportunity to bring more relational interaction around the Bible, YouVersion introduced community features such as a home feed of friends' activity and the ability to study the Bible together. Through Plans with Friends, people can connect and discuss the Bible when they aren't in the same room, or even the same country. This feature helped change the life of a New Jersey native, Adora, who used the Bible App to rebuild a relationship with her mother.

"When I started using the Bible App, I hadn't seen or spoken to my mother in 10 years," said Adora. "After several months of reading Bible Plans about forgiveness and healing, I decided to offer my mom a relationship with me-but only in the Bible App."

Adora added her mother as a Friend in the Bible App and sent an invitation to do a Bible Plan together using the Plans with Friends feature. As they talked about what they were reading, they opened up about mutual feelings of hurt and anger. They slowly went from only talking in the Bible App, to texting, and then meeting in person to pray.

"I never, ever thought that I would have a relationship with my mom again," said Adora. "But by reading the Bible and doing these daily plans, God has worked a miracle on my heart and in my life."

Beyond shaping the way we interact with Scripture and each other, the Bible App has introduced a way for the Bible to reach us in our everyday lives. Features like Verse of the Day notifications, reading reminders, and daily Streaks have helped people develop new Bible-reading habits, sometimes after years of trying to do so on their own.

"When people install the Bible App, it's usually because they want to read it more. So we've spent a lot of time thinking about how to help them do what they want to do," said Gruenewald. 

Each new feature is targeted to increase daily engagement from the YouVersion community. Since adding features like daily Streaks and Perfect Weeks, the number of daily active users has increased by more than 30 percent compared to last year.

"These last 10 years have been more than we could ask, think, or imagine, and we believe this is only the beginning," said Gruenewald. "As we look ahead, we're excited about the new ways God is using technology to help people make even more connections between the Bible and their daily lives."

YouVersion will soon launch Bible Lens, a new app that analyzes the objects in a photo and detects biblical themes to suggest the Bible verse that best fits the photo. Then, it automatically designs a high-quality Verse Image that can be shared with friends. Additionally, the app will have the ability to create Verse Images from photos saved in a person's camera roll to help them rediscover every moment of their life through the lens of the Bible.

Visit blog.youversion.com to stay updated on YouVersion and its products.

About YouVersion             
YouVersion was created by Life.Church to help people engage with the Bible. The team designs and builds experiences that make it easy for people to integrate the Bible into their everyday lives. Since 2008, the Bible App has offered a free Bible experience on smartphones, tablets, and computers that allows people to read the Bible at any time and in any place. In 2013, YouVersion launched the Bible App for Kids, in partnership with OneHope, to engage children with beautifully illustrated, interactive Bible adventures. For more information about YouVersion, visit www.youversion.com.

Rachel Feuerborn 
405-216-7072 
press@youversion.com

Photos accompanying this announcement are available at

http://www.globenewswire.com/NewsRoom/AttachmentNg/f30266ec-0b9d-4f60-ab42-9873bd1a7cdc

http://www.globenewswire.com/NewsRoom/AttachmentNg/463935be-157a-4c29-ba41-d011cdd62e3d




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: YouVersion via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum